Raymond Byrd CEO Role and Compensation
Raymond Byrd serves as the Chief Executive Officer of Spark Therapeutics, a Philadelphia-based biotechnology company focused on gene therapies for rare diseases. His total annual compensation includes a base salary, equity awards, and other forms of pay reported in regulatory filings SEC filing for Spark Therapeutics.
Executive compensation at Spark Therapeutics is structured to align leadership incentives with long-term shareholder value, clinical milestones, and regulatory approvals. Byrd's pay package reflects the company's focus on commercializing treatments for conditions such as hemophilia and inherited retinal dystrophies Forbes on biotech CEO compensation.
Spark Therapeutics Under Raymond Byrd
Under Raymond Byrd's leadership, Spark Therapeutics has advanced its pipeline of gene therapies targeting rare genetic diseases. The company's commercial portfolio includes treatments for hemophilia A and B, and it continues to expand its research in inherited retinal conditions.
Spark Therapeutics operates as a subsidiary of Roche, following a major acquisition that strengthened its global commercial and manufacturing capabilities. This structure allows the company to leverage Roche's infrastructure while maintaining a focused mission on gene therapy innovation Roche official website.
Raymond Byrd Career Background
Before leading Spark Therapeutics, Raymond Byrd held senior roles in the biotechnology and pharmaceutical industries, with experience in commercial operations and strategic growth. His career includes leadership positions at companies involved in rare disease therapies and advanced therapeutics.
Byrd's background combines expertise in business leadership, gene therapy commercialization, and rare disease market access. His tenure at Spark Therapeutics emphasizes execution of clinical and commercial strategies for approved therapies Spark Therapeutics official website.